

Investment into US life sciences expanding rapidly

Data provided by **PitchBook**



Corporate, PE & late-stage life sciences VC deal activity



Source: PitchBook | Geography: US
*As of June 22, 2021

“Innovation in life sciences across the US has benefited from the increasing sophistication of late-stage VC and growth equity investors—innovation that was very much at the forefront of vaccines developed to combat COVID-19.”


PETER BRAVERMAN, VP GLOBAL VENUE SALES

Life sciences deals (\$B) by type



Source: PitchBook | Geography: US
*As of June 22, 2021

Life sciences deals (#) by type



Source: PitchBook | Geography: US
*As of June 22, 2021



\$17.1B

Sum generated by investment into US-based life sciences companies through June 22 across 463 completed deals



26.5%

Share of capital committed in 2020 to life sciences companies in 2020's market-leading region San Jose-San Francisco-Oakland, CA, representing \$7.8 billion in total



\$7.1B

Tally of investment into drug discovery platforms across 143 transactions closed YTD, the leading sector for funding activity within life sciences in the US since 2017



65%

Share of overall funding for life sciences coming from late-stage VC investment at \$19 billion committed across 627 financings, some 75% of all deals closed in 2020



\$10.3B


Exit value generated YTD by PE-backed life sciences companies in the US, already surpassing the \$10.1 billion in value generated by PE-backed life sciences companies in all of 2020



163


The number of investments made by PE firm OrbiMed, the most prolific investor of any type into US-based life sciences companies since the start of 2006

Life sciences deals (\$) by sector



Source: PitchBook | Geography: US
*As of June 22, 2021

Life sciences deals (#) by sector



Source: PitchBook | Geography: US
*As of June 22, 2021